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Abstract
Background: The initial systolic blood pressure (SBP) in patients presenting to the hospital with acute heart 
failure (AHF) informs prognosis, diagnosis, and guides initial treatment. However, over time AHF presentations with 
elevated SBP appear to have declined. The present study examined whether the frequency of AHF presentations 
with systolic hypertension (SBP >160 mmHg) declined over a nearly two-decade time interval. 
Methods: This study compares four historical, cross-sectional cohorts with AHF who were admitted to tertiary 
care medical centres in the North-eastern USA in 1995, 2000, 2006, and 2011-13. The main outcome was the 
proportion of AHF patients presenting with an initial SBP >160 mmHg. 
Results: 2,366 patients comprised the study sample. The average age was 77 years, 55% were female, 94% 
white, and 75% had prior heart failure. In 1995, 34% of AHF patients presented with an initial SBP >160 mmHg 
compared to 20% in 2011-2013 (p<0.01). Multivariate logistic regression demonstrated reduced odds of presenting 
with a SBP >160 mmHg in 2006 (0.64, 95% CI 0.42-0.96) and 2011-13 (0.46, 95% CI 0.28-0.74) compared with 
patients in 1995. 
Conclusion: The proportion of patients with AHF and initial SBP >160 mmHg significantly declined over the 
study time period. There are several potential reasons for this observation and these findings highlight the need for 
ongoing surveillance of patients with AHF as changing clinical characteristics can impact early treatment decisions.
Keywords: Acute heart failure; Systolic blood pressure; Emergency
department; Epidemiology
Abbreviations: AHF: Acute Heart Failure; SBP: Systolic Blood 
Pressure; ED: Emergency Department; WHFS: Worcester Heart Failure 
Study
Introduction
Worldwide, over 20 million people have chronic heart failure 
(HF) [1]. Patients with HF are prone to recurrent acute HF (AHF) 
exacerbations, and in the United States the majority of such 
patients are cared for in an emergency department (ED). Acute HF 
presentations account for nearly one million visits [2] and hospital 
admissions annually in the U.S. alone [3,4]. Efficiently diagnosing 
AHF and initiating appropriate therapies for patients with AHF can 
be challenging since multi-morbidity is common in patients with HF. 
However, several clinical parameters available at the time of hospital 
presentation, including history, exam, lab testing, xray, EKG, and point 
of care ultrasound, provide information that is useful in diagnosing 
the presence of AHF and guiding treatment [5]. Expert opinion has 
suggested that the initial, ED management of patients with AHF be 
based on the patient’s clinical profile [6]. This is, in part, influenced by 
vital signs at the time of presentation and in particular presenting blood 
pressure (BP) [7,8]. 
Historically the majority of patients with AHF present to the hospital 
with either elevated or normal blood pressure (BP) [7-9]. These initial 
BP values can be used to classify patients as having either “vascular 
failure,” as defined by a systolic blood pressure (SBP) of >160 mmHg, or 
“cardiac failure,” as defined by a normal or low SBP (e.g., <150 mmHg) 
[9,10]. Although far from an exact science, presenting blood pressure 
profile is related to type of HF, with patients having preserved ejection 
fraction (HFpEF) more commonly presenting with an elevated SBP 
[5,9]. Since treatment decisions about AHF must frequently be made 
in the ED without echocardiographic data, SBP represents a potential 
initial guide for early AHF management. 
Epidemiological studies suggest that the clinical characteristics, 
management, and prognosis of patients with HF have changed over the 
past several decades. Compared to prior years, contemporary patients 
presenting with AHF are older, have a greater comorbidity burden, 
and have increased short and longer-term survival [11]. Although the 
prognosis from HF has improved over time, rates of hospital admission 
for HF are not in decline, suggesting that AHF remains a common and 
costly condition. Between the 1990s and the mid-2000s it appeared that 
there was a decline in the number of patients presenting with AHF and 
elevated systolic hypertension on admission. We undertook the present 
study to examine whether there was indeed a historical change in the 
frequency of AHF presentations with systolic hypertension (SBP >160 
mmHg) on arrival to the ED in 4 historical, cross-sectional, cohorts 
between 1995 and 2013. 
Methods
Study population sources
We derived our study population from data collected on patients 
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seen in the EDs of 3 teaching hospitals in Worcester, MA (USA) and 
subsequently admitted to the hospital with a diagnosis of AHF. Two 
National Institute of Health sponsored research projects, conducted by 
members of the same research group, contributed to the database for 
the present study. The first study was the Worcester heart failure study 
(WHFS) which was a large, multi-center investigation that documented 
the clinical characteristics, treatments, and outcomes of adult patients 
admitted with AHF to all medical centers in central Massachusetts over 
multiple study years between 1995 and 2006 [11,12]. The second study 
was an ED-based extension of the WHFS using similar methodology 
and was conducted from 2011-2013. Both studies conform with the 
principles outlined in the Declaration of Helsinki and underwent full 
review by the Committee for the Protection of Human Subjects in 
Research at the University of Massachusetts Medical School. All study 
activities described below were approved, and all subjects either signed 
a written informed consent document prior to participation or were 
considered exempt.
Additional Study Details
The Worcester heart failure study 
The WHFS collected data on adult patients admitted to multiple 
(n=11) hospitals in central Massachusetts (MA) over several study years 
between 1995 and 2006 [11,12]. For the present study, we restricted the 
WHFS sample to patients admitted in 1995, 2000, and 2006 to three 
teaching hospitals in Worcester, MA. Patients in the WHFS were 
identified by trained study staff who performed a standardized review 
of the medical records of patients with primary and/or secondary 
International Classification of Diseases (9th Revision) diagnoses 
consistent with a possible admission for AHF. Patients who were 
discharged with the HF code of (428.XX) were used as the primary 
means for identifying cases of possible AHF. Subsequently only cases 
that met the Framingham criteria for HF were included in the final 
dataset [13].
ED-based study
The ED-based, observational, investigation began in September 
2011, and enrolled patients over 2 years from same teaching hospitals 
included in the WHFS. Patients were identified and initially enrolled in 
the ED by trained study staff based on history, physical exam, physician 
impression, and lab values consistent with the occurrence of possible 
AHF. The HF diagnosis was confirmed (or refuted) by subsequent chart 
review based on whether the subject met Framingham criteria for AHF 
as in the WHFS. 
Inclusion and exclusion criteria 
Only adult (>18) patients admitted to one of the study teaching 
hospitals after being evaluated in the ED were included for both the 
WHFS and ED enrolled patients. As mentioned, our diagnostic 
criterion for AHF was the Framingham criteria which were chosen 
because it has been used in several studies, including the WHFS, [14,15] 
and is straightforward to apply. These criteria include the presence of 
2 major (e.g. radiological evidence of pulmonary edema) or 1 major 
and 2 minor (e.g. extremity oedema, exertional dyspnoea) criteria [13]. 
Subjects were excluded if they had hypotension (SBP <95 mmHg) or 
cardiogenic shock, or if they were on haemodialysis.
Data collection activities
Both contributing studies collected the majority of their data 
from structured chart reviews. Data included patients’ demographic 
characteristics, past medical history, physical exam findings, vital signs, 
home medications, clinical characteristics, admission status (e.g., ICU 
versus floor), and laboratory results. For the main variable of interest, 
SBP, we used the first available reading obtained after the patient arrived 
at the hospital ED. The chart review also obtained information on 
short-term clinical outcomes including inpatient length of stay (LOS), 
need for ICU admission, endotracheal intubation, complications, and 
ejection fraction findings. 
Data Analysis 
Methods used to summarize the data
A total of 338 subjects were available from the ED-based AHF 
study for analysis. To increase statistical power, we took a 2:1 random 
sample of subjects from each WHFS year (compared to the ED-based 
study) which resulted in a total of 676 patients in each WHFS cohort 
(1995, 2000, 2006) (Figure 1). Differences in the demographic and 
clinical characteristics of patients in each of the four study groups 
were compared by chi-square tests for categorical and ANOVA for 
continuous variables (SAS, Cary, NC).
Methods used to test the principal study hypothesis
Our primary study endpoint was the percentage of patients 
presenting to the ED with AHF who had a SBP >160 mmHg during each 
of the years under study. Our hypothesis was that the frequency of AHF 
presentations accompanied by hypertension (SBP >160 mmHg) had 
declined over the study interval. We used a SBP cutoff of >160 mmHg 
because it was the highest BP category defined in the OPTIMIZE-HF 
registry study [9]. In published guidelines it identifies patients with AHF 
who are in a low risk group, [16] and also because this group would be 
most likely to require acute treatment to lower their BP in the ED. For 
the univariate analyses, differences in the average SBP at the time of ED 
presentation according to study year were compared by chi-square tests 
of statistical significance. In addition, a multivariate logistic regression 
analysis was performed to examine whether study year was associated 
with a decrease in hypertensive AHF presentations over time at a SBP 
cut point of 160 mmHg. We set 1995 as the referent year and created 
a multiple logistic regression model by adding potential confounding 
variables to the analysis based on clinical relevance and a p value of 
<0.20 on univariate examination. These factors included age, sex, 
race, body mass index, hematocrit, outpatient medications, a history 
of hypertension, atrial fibrillation, diabetes mellitus, kidney disease, 
and hypercholesterolemia. We also considered additional confounding 
factors of prognostic importance that have been shown to be associated 
with mortality and other clinical outcomes in patients with AHF 
Subjects identied and Screened for Framingham Criteria for AHF
2011-13 ED AHF
study  database
2006 WHFS
database
2000 WHFS
database
1995 WHFS
database
Inclusion and exclusion criteria applied
n=1710
n=676
n=2366
n=676n=676n=338
n=1914 n=1331
2:1 random sample based on   ED study
Figure 1:  Diagram of subject enrolment.
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[17,18]. Of note, EF findings were missing in 58% of the study sample 
and were not controlled for in the regression models. Similarly, B-type 
natriuretic peptide (BNP) levels were not available in the 1995 and 2000 
study cohorts and were not included in our regression analyses. 
Results
Characteristics of the entire study population
A total of 2,366 individuals admitted with AHF comprised our 
study population (Figure 1). The average age of this population 
was 77 years, 55% were female, 92% were white, and 75% had been 
previously diagnosed with HF. Between 1995 and 2011-13 there 
were several notable changes in the clinical characteristics of these 
patients. Compared to patients admitted in 1995, patients in the more 
recent study years of 2011-13 were significantly more likely to have a 
history of hypertension, atrial fibrillation, chronic kidney disease, and 
hyperlipidemia. These patients were also more likely to be taking ACE-
Inhibitors and beta-blockers and have a shorter length of hospital stay, 
but were less likely to be taking digoxin than patients in 1995 (Table 1).
Trends in the characteristics of patients with SBP >160 mmHg 
Among patients with AHF and a SBP >160 mmHg, the average age 
was 76 years, 61% were female, and 91% were white. Consistent with 
the findings in the entire study sample, between 1995 and 2011-13 the 
characteristics of patients with AHF and a presenting SBP >160 mmHg 
also changed. In more recent study years, AHF patients with systolic 
hypertension on presentation were less likely to be women, more likely 
to have a shorter LOS and a lower mean SBP on admission, and fewer 
were prescribed digoxin (Table 2).
Mean SBP and the frequency of elevated SBP over time
The SBP at presentation averaged 151 mmHg in 1995 and decreased 
over time to 140 mmHg by 2011-2013 (p<0.01). In 1995, 33.6% of all 
AHF patients had a SBP>160 mmHg which decreased to 19.5% by 
2011-2013 (p<0.01) (Figure 2). 45% of patients had ejection fraction 
(EF) measured during their index inpatient admission. For the subset 
of patients with EF measurements, SBP trends were analyzed by either 
preserved (≥50%) or reduced (≤40%) EF. In patients with reduced 
EF, average SBP declined from 152 mmHg in 1995 to 138 mmHg in 
2011-13 (p=0.03). However, for those patients with preserved EF SBP 
declines were much less significant and averaged 156 mmHg in 1995 
and 149 mmHg in 2011-13.
Study Year
1995 2000 2006 2011-13 p-value
Demographics (n=676) (n=676) (n=676) (n=338)
Age (mean, yrs) 76.7 76.9 77.6 74.8 <0.01
Female (%) 57.9 56.7 56.4 41.2 <0.01
White (%) 95.9 91.4 90.1 89.6 <0.01
Body mass index (kg/m2) 26.9 27.7 28.0 31.7 <0.01
Medical /Surgical History (%)
Hypertension 64.4 68.1 82.7 89.4 <0.01
Atrial fibrillation 36.7 36.7 45.9 53.9 <0.01
Diabetes mellitus 39.5 38.2 37.9 52.7 <0.01
Coronary heart disease 56.7 58.4 58.1 58.3 0.6
Chronic pulmonary 
disease 38.0 34.6 40.1 35.8 0.6
Stroke 15.8 16.4 14.1 18.6 0.9
Chronic kidney disease 20.6 22.0 36.5 46.5 <0.01
Heart failure 75.3 73.3 79.1 71.9 0.6
Hypercholesterolemia 14.4 24.9 53.3 73.7 <0.01
Mean EF (%) 40.7 43.2 47.3 44.4 0.51*
Home Medications (%)
ACE-Inhibitors 39.1 36.1 39.6 55.9 <0.01
Beta Mockers 21.3 40.4 64.4 74.9 <0.01
ACE-I + Beta Stockers 7.0 17.5 28.7 44.4 <0.01
Calcium Channel 
Blockers 33.6 24.0 23.8 26.3 <0.01
Diuretics (any) 70.4 66.7 72.0 77.5 <0.01
Digoxin 39.9 33.1 18.1 18.3 <0.01
Laboratory findings
Creatinine 1.5 1.5 1.5 1.6 0.5
Hematocrit (%) 37.2 36.2 35.3 35.1 <0.01
# - missing data in >50% of patients, ACE-I= angiotensin converting enzyme- 
inhibitor, Creatinine (mg/dl)
Table 1: Selected demographic and clinical characteristics of the entire study 
sample.
 
Study Year
1995 2000 2006 2011-13
p-value
 Demographics (n=227 ) (n=189 ) (n=143 ) (n=66)
Age (mean, yrs) 76.8 76.4 76.7 73.5 0.25
Female (%) 66.5 61.4 53.9 54.6 <0.01
White (%) 96 87.3 89.5 90 0.09
Body mass index (kg/m2) 27.9 28.6 28.3 33.4 <0.01
Medical/Surgical History (%)
Hypertension  75.3 77.8 88.1 93.9 <0.01
Atrial fibrillation 32.6 29.6 30.8 45.5 0.23
Diabetes mellitus 44.9 42.3 39.9 50 0.96
Coronary heart disease 55.1 57.1 49 54.6 0.36
Chronic obstructive pulmonary 
disease 35.2 31.2 34.3 25.8 0.36
Stroke 18.1 12.1 16.8 25.8 0.27
Chronic kidney disease 19.8 22.8 37.8 42.4 <0.01
Heart failure 72.3 66.1 72 60.6 0.35
Hyperlipidemia 19.4 25.4 48.3 74.2 <0.01
Home Medications (%)
 ACE-Inhibitors 36.1 34.4 39.9 62.1 <0.01
Beta Blockers 26.9 48.2 62.9 77.3 <0.01
ACE-I + Beta Blockers 7.5 21.1 29.4 50 <0.01
Digoxin 36.6 26.5 14 7.6 <0.01
Diuretics (any) 64.8 56.6 60.1 69.7 0.81
Laboratory findings
Creatinine, mean (mg/dl) 1.46 1.5 1.5 1.55 0.8
Hematocrit mean (%) 38.1 36.9 36.2 35.9 0.03
** data missing in 55% of cases
Table 2: Selected demographic and clinical characteristics of patients of patients 
with a SBP >160 mmHg on presentation.
Figure 2: Percent of patients with AHF presenting with systolic blood pressure 
>160 mHg over time.
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The distribution of SBP across four BP strata has also changed over 
time. Patients hospitalized with AHF during more recent years (after 
2006) demonstrated a more balanced and even distribution of SBP than 
earlier years where a greater percentage of patients fell into the higher 
(>140 mmHg and >160 mmHg) SBP strata (Figure 3).
When compared to patients hospitalized in 1995 (referent year), 
the crude odds ratios demonstrated that there was a significantly 
lower odds of patients with AHF presenting with SBP >160 mmHg in 
2000, 2006, and 2011-2013. After adjustment for several demographic, 
medical history, and clinical factors, only the 2006 and 2011-13 cohorts 
were found to have a significantly reduced odds of presenting with a 
SBP >160 mmHg (Table 3).
Discussion
In the present study we compared the frequency of patients with 
AHF presenting to the ED with SBP greater than 160mmHg in four 
cross-sectional study cohorts between 1995 and 2011-13. The rationale 
for studying presenting SBP at presentation for patients with AHF is 
to try to understand if there was a change in the epidemiology of these 
patients over time and because of expert recommendations to use SBP 
as a guide to early diagnostic and treatment approaches. Our results 
demonstrate that there was a significant decrease over our study time 
period in the proportion of AHF patients who present with SBP >160 
mmHg, as well as a similar decrease in the mean SBP over greater than 
15 years beginning in 1995. 
Despite a decrease in the proportion of patients with an SBP 
>160 mmHg over time, the overall mean SBP results we observed 
are consistent with other observational studies of patients with AHF 
conducted in the same time period. The acute decompensated heart 
failure national registry (ADHERE) collected data on patients with AHF 
who were admitted to 263 medical centers from all regions of the United 
States between 2001 and 2006. In ADHERE, patients admitted between 
2001 and 2003 were found to have a mean initial SBP of 144 mmHg 
which falls between our mean SBP’s for 2000 and 2006 which were 
147 mmHg and 141 mmHg respectively [19]. Similarly, the organized 
program to initiate lifesaving treatment in hospitalized patients with 
heart failure (OPTIMIZE-HF) national registry found that the average 
SBP of patients admitted with AHF in 2003 and 2004 was 143 mmHg. 
Although we found a decline in the initial SBP of patients with AHF 
over our study time-period it is important to note that most still had 
normal to elevated SBP at the time of hospital arrival. Our results also 
suggest that patients with preserved ejection fraction were the least 
affected by this overall trend of reduced initial SBP over time. 
The importance of SBP in providing a framework for clinicians to 
clinically categorize and better manage patients with AHF has been 
discussed in several studies [5,7,8]. The OPTIMIZE-HF registry of 
nearly 50,000 patients found that patients with higher SBP’s were more 
likely to be female, African American, and to have heart failure with 
a preserved ejection fraction [9]. OPTIMIZE-HF also documented 
the relationship between initial SBP and short-term (inpatient) and 
post discharge prognosis, where patients having higher SBPs (>140 
mmHg) were found to have a decreased mortality compared with 
patients in lower SBP strata [9]. Lastly, an American Heart Association 
working group focusing on the diagnosis and treatment of AHF in 
the ED setting has advocated an approach whereby SBP is central to 
early risk stratification with patients having a SBP>160 mmHg falling 
into the lowest risk prognostic group [16]. Moreover, prior literature 
has characterized patients with AHF and significantly elevated SBP as 
having “vascular failure” rather than “cardiac failure”. This distinction 
is helpful to clinicians as they attempt to distinguish between patients 
with different treatment needs [8,20]. The vascular failure patient 
typically does not have significant total body fluid overload and, as 
a result, early treatment focuses on afterload reduction rather than 
intensive diuresis [8,20]. 
It is unclear why the proportion of patients with AHF and 
hypertension underwent the historical decline we observed. However, 
our data demonstrates that many demographic and clinical features of 
these patients have also changed during the last few decades. Since 1995, 
patients enrolled in studies of AHF in our geographic area have become 
older, have a greater comorbid disease burden, but have an improved 
post discharge prognosis [21]. Similarly, other studies have documented 
improvement in the long-term survival of patients discharged from the 
hospital after AHF treatment [22,23]. A large North American study 
of more than 55 million Medicare patients discharged with a diagnosis 
of AHF found that admission rates for AHF declined significantly 
between 1998 and 2008, perhaps reflecting improved management of 
these patients [3]. Overall these changes may partly explain our results.
However, other factors may also explain our findings. First, the 
outpatient management of heart failure changed significantly while 
our data was collected [24,25]. There is also increased recognition 
that outpatient hypertension management in HF patients can decrease 
the incidence rate of AHF presentations [26]. In our sample there 
was a steady increase in the use of ACE-Inhibitors and beta-blockers 
in isolation and in combination over time. Others have documented 
similar increases in the use of these medications over time [27]. It is 
unclear how the outpatient management of patients with HF influences 
the SBP when a patient presents with AHF, but it may, in part, explain 
the trends we observed. 
Figure 3: Distribution of systolic blood pressure (mmHg) by study year.
Year Crude OR Adjusted OR*
19950 1 1
2000
0.7 0.94
(0.54-0.90)$ (0.67-1.31)
2006
0.41 0.64
(0.30-0.55) (0.42-0.96)
2011-13
0.35 0.46
(0.23-0.52) (0.28-0.74)
* adjusted for the following variables: age, sex, race, body mass index, 
hypertension, atrial fibrillation, diabetes mellitus, kidney disease, 
hypercholesterolemia, outpatient medication (ace-inhibitors, beta-blockers, 
diuretics, digoxin, calcium channel blockers, hematocrit; 0 1995 is the referent 
year; $ 95% CI
Table 3: Crude and adjusted odds ratios for patients presenting with a SBP >160 
mmHg.
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Lastly, the management of hypertension has changed significantly 
with new definitions of hypertension and targets for therapy proposed 
with each Joint National Committee on the Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC) update since 1977 [28]. In 
our study, we found a significant increase in the proportion of patients 
with pre-existing hypertension over time which likely reflects the 
increased comorbid disease burden in these patients, the changing 
definitions of hypertension, and the heightened focus on this disease. 
Since hypertension is an important cause of heart failure, and blood 
pressure control has improved over time, these changing trends may 
have influenced our results [28,29].
Study Strengths and Limitations
The major strength of this study lies in its ability to combine 
detailed current and historical data in order to better understand how 
the presentation of patients with AHF may have changed over time. 
However, there are several limitations that should be considered 
when interpreting our findings. First, the WHFS data were compared 
to an ED-based AHF study and there were some differences in how 
the patients were identified. Such heterogeneity could introduce a 
potential selection bias. However, the significant trend in reduction 
of hypertensive presentations in patients with AHF was also observed 
when only considering the most recent WHFS cohort (2006) (excluding 
ED-based 2011-13 data), reinforcing the likelihood of our observed 
trends being real. Secondly there was no standard method by which 
the patient’s initial SBP was measured although this limitation would 
have been consistent across all study years. Third, ejection fraction 
(EF) is an important variable that is related to presenting SBP, but 
data on EF were missing in a large proportion of subjects and was not 
included in our regression models. Similarly, BNP was not obtained in 
the first 2 patient cohorts due to it not being used at all the study sites. 
Changes in prehospital treatment may also have influenced the initial 
presenting SBP’s, but the proportion of patients with AHF transported 
by ambulance has not significantly changed over time (data not shown). 
Patient with a SBP <95 mmHg was excluded from both studies due to 
the initial goals of the ED-based research protocol. This could result in 
the mean SBP’s we report to be somewhat higher than values reported 
in other studies. This study was also conducted in a single region in 
the USA, which may limit the generalizability of our findings to other 
geographic areas where the racial, socio-demographic, and clinical 
characteristics of patients differ. 
Conclusion
Our study demonstrates that the proportion of patients with AHF 
accompanied by a SBP >160 mmHg at the time of presentation to the 
hospital declined significantly between 1995 and the late 2000s. In 
addition, the mean SBP at presentation also declined over the nearly 
2 decade period covered under this study. Why these changes have 
occurred is unknown, but they are likely a result of the changes that 
have occurred in the outpatient management of both heart failure and 
hypertension over the last 15-20 years. It also highlights the need for 
ongoing surveillance studies of patients with AHF as the risk of HF 
increases in prevalence with the aging of the population. 
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